Zemcelpro® is conditionally authorized by the European Commission for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available Zemcelpro® will increase access to allogeneic stem cell transplantation to treat life-threatening haematologic malignancies, including leukemias and myelodysplastic syndromes Timing of … Continue reading Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells